000			04563nam a22005897a 4500
008			171110s20172017 xxu||||| |||| 00| 0 eng d
022			_a0732-183X
040			_aOvid MEDLINE(R)
099			_a29072977
245			_aLong-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.
251			_aJournal of Clinical Oncology. 35(35):3942-3948, 2017 Dec 10
252			_aJ Clin Oncol. 35(35):3942-3948, 2017 Dec 10
253			_aJournal of clinical oncology : official journal of the American Society of Clinical Oncology
260			_c2017
260			_fFY2018
266			_d2017-11-10
501			_aAvailable online from MWHC library: 1999 - present, Available in print through MWHC library: 1999 - 2008
520			_aPurpose Early cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab. However, objective measures of cardiac function and health-related quality of life are lacking in long-term follow-up of patients who remain cancer free after completion of adjuvant treatment. Patients and Methods Patients in NSABP Protocol B-31 received anthracycline and taxane chemotherapy with or without trastuzumab for adjuvant treatment of node-positive, human epidermal growth factor receptor 2-positive early-stage breast cancer. A long-term follow-up assessment was undertaken for patients who were alive and disease free, which included measurement of left ventricular ejection fraction by multigated acquisition scan along with patient-reported outcomes using the Duke Activity Status Index (DASI), the Medical Outcomes Study questionnaire, and a review of current medications and comorbid conditions. Results At a median follow-up of 8.8 years among eligible participants, five (4.5%) of 110 in the control group and 10 (3.4%) of 297 in the trastuzumab group had a > 10% decline in left ventricular ejection fraction from baseline to a value < 50%. Lower DASI scores correlated with age and use of medications for hypertension, cardiac conditions, diabetes, and hyperlipidemia, but not with whether patients had received trastuzumab. Conclusion In patients without underlying cardiac disease at baseline, the addition of trastuzumab to adjuvant anthracycline and taxane-based chemotherapy does not result in long-term worsening of cardiac function, cardiac symptoms, or health-related quality of life. The DASI questionnaire may provide a simple and useful tool for monitoring patient-reported changes that reflect cardiac function.
546			_aEnglish
650			_a*Antineoplastic Combined Chemotherapy Protocols/ad [Administration & Dosage]
650			_a*Breast Neoplasms/dt [Drug Therapy]
650			_a*Breast Neoplasms/pp [Physiopathology]
650			_a*Cardiovascular System/pp [Physiopathology]
650			_a*Receptor, ErbB-2/bi [Biosynthesis]
650			_aAntineoplastic Combined Chemotherapy Protocols/ae [Adverse Effects]
650			_aBreast Neoplasms/en [Enzymology]
650			_aBreast Neoplasms/pa [Pathology]
650			_aChemotherapy, Adjuvant
650			_aCohort Studies
650			_aCyclophosphamide/ad [Administration & Dosage]
650			_aCyclophosphamide/ae [Adverse Effects]
650			_aDoxorubicin/ad [Administration & Dosage]
650			_aDoxorubicin/ae [Adverse Effects]
650			_aFemale
650			_aFollow-Up Studies
650			_aHumans
650			_aLymphatic Metastasis
650			_aMiddle Aged
650			_aPaclitaxel/ad [Administration & Dosage]
650			_aPaclitaxel/ae [Adverse Effects]
650			_aQuality of Life
650			_aTrastuzumab/ad [Administration & Dosage]
650			_aTrastuzumab/ae [Adverse Effects]
650			_aVentricular Dysfunction, Left/pp [Physiopathology]
651			_aWashington Cancer Institute
657			_aJournal Article
700			_aSwain, Sandra M
700			_aZapas, John L
790			_aAtkins JN, Biggs DD, Brufsky AM, Cecchini RS, Fehrenbacher L, Flynn PJ, Ganz PA, Geyer CE Jr, Gross HM, Jeong JH, Mamounas EP, Polikoff J, Rastogi P, Romond EH, Seay TE, Swain SM, Wade JL 3rd, Wahl TA, Wolmark N, Zapas JL
856			_uhttps://dx.doi.org/10.1200/JCO.2017.74.1165 _zhttps://dx.doi.org/10.1200/JCO.2017.74.1165
942			_cART _dArticle
999			_c3020 _d3020